Wishlist: SOMAscan analysis of plasma samples from breast cancer patients
Forecast New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $25,000 to $250,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541720 Research and Development in the Social Sciences and Humanities
- Points of contact
-
- NCTR Acquisition Liaison nctracquisitions@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration is procuring SOMAscan analysis of plasma samples from breast cancer patients treated with doxorubicin to assess cardiotoxicity biomarkers. The solicitation is estimated to release on May 1, 2027, with award anticipated on June 1, 2027. This is a new requirement under NAICS 541720 (Research and Development in the Social Sciences and Humanities) with no set-aside applied.
The estimated award value ranges from $25,000 to $250,000. Interested contractors should direct inquiries to the FDA Acquisition Liaison at nctracquisitions@fda.hhs.gov.
Forecast text
Cardiotoxicity biomarker analysis of plasma samples from breast cancer patients treated with doxorubicin
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast